Evidence map›Paper›PMID 40134302›Full record

ReviewChemical Society reviews2025

A surface chemistry perspective on SERS: revisiting the basics to push the field forward.

Chiara Deriu, Laura Fabris

Abstract readReview
In one paragraph

Review in Chemical Society reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Strategies for Multiplexing Plasmonic Biosensing.Sensors (Basel, Switzerland) · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chiara DeriuDepartment of Applied Science and Technology, Politecnico di Torino, 10129 Turin, Italy. chiara.deriu@polito.it.ORCID http://orcid.org/0000-0003-3077-5029
Laura FabrisDepartment of Applied Science and Technology, Politecnico di Torino, 10129 Turin, Italy. chiara.deriu@polito.it.ORCID http://orcid.org/0000-0002-7089-5175

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surfaces are well known to be complex entities that are extremely difficult to study, and any phenomenon that is related to them is consequently challenging to approach. Moving from the bulk to the nanoscale adds a further layer of complexity to the problem. Because SERS relies on surfaces at the nanoscale, a rigorous understanding of the chemical phenomena that concur in the observation of the SERS signal is still limited or disorganized at best. Specifically, the lack of understanding of the chemical properties of nanoparticle surfaces has direct consequences on the development of SERS-based devices, causing a widespread belief that SERS is an inherently unreliable and fundamentally irreproducible analytical technique. Herein, we discuss old and new literature from SERS and related fields to accompany the reader through a journey that explores the chemical nature and architecture of colloidal plasmonic nanoparticles as the most popular SERS-active surfaces. By examining the chemistry of the surface landscape of the most common SERS colloids and the thermodynamic equilibria that characterize it, we aim to paint a chemically realistic picture of what a SERS analyst deals with on a daily basis. Thus, our goal for this review is to provide a centralized compilation of key, state-of-the-art surface chemistry information that can guide the rational development of analytical protocols and contribute an additional path through which our community can continue to advance SERS as a reliable and robust analytical tool.

Identifiers

PMID40134302
PMCPMC11937889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.